Eupraxia Pharmaceuticals Inc. (EPRX.TO)
CAD 5.51
(0.18%)
CAD 5.51
(0.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -37.39 Million CAD | -63.75% |
| 2022 | -22.13 Million CAD | -8.09% |
| 2021 | -21.96 Million CAD | -875.17% |
| 2020 | -2.01 Million CAD | 64.19% |
| 2019 | -5.94 Million CAD | 58.1% |
| 2018 | -14.56 Million CAD | -190.42% |
| 2017 | -4.88 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -8.91 Million CAD | 36.0% |
| 2024 Q1 | -8.97 Million CAD | 14.66% |
| 2023 Q3 | -8.57 Million CAD | -15.93% |
| 2023 FY | - CAD | -67.9% |
| 2023 Q4 | -6.34 Million CAD | 26.04% |
| 2023 Q2 | -7.39 Million CAD | -54.11% |
| 2023 Q1 | -4.79 Million CAD | 43.67% |
| 2022 Q2 | -5.97 Million CAD | -80.28% |
| 2022 Q4 | -8.51 Million CAD | -84.19% |
| 2022 FY | - CAD | -8.09% |
| 2022 Q1 | -3.31 Million CAD | 1.52% |
| 2022 Q3 | -4.62 Million CAD | 22.64% |
| 2021 Q2 | -5.26 Million CAD | 25.92% |
| 2021 Q4 | -3.36 Million CAD | 32.82% |
| 2021 Q1 | -7.11 Million CAD | -17782.21% |
| 2021 FY | - CAD | -875.17% |
| 2021 Q3 | -5.01 Million CAD | 4.82% |
| 2020 Q2 | -654.4 Thousand CAD | 30.62% |
| 2020 FY | - CAD | 64.19% |
| 2020 Q4 | -39.76 Thousand CAD | 93.21% |
| 2020 Q3 | -585.39 Thousand CAD | 10.54% |
| 2020 Q1 | -943.16 Thousand CAD | -240.0% |
| 2019 Q3 | -1.51 Million CAD | 0.0% |
| 2019 FY | - CAD | 58.1% |
| 2019 Q4 | -277.4 Thousand CAD | 81.72% |
| 2018 FY | - CAD | -190.42% |
| 2017 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Appili Therapeutics Inc. | -2.09 Million CAD | -1683.812% |
| Helix BioPharma Corp. | -9.38 Million CAD | -298.29% |
| Microbix Biosystems Inc. | 1.95 Million CAD | 2010.793% |
| Medicenna Therapeutics Corp. | -18.67 Million CAD | -100.297% |
| Satellos Bioscience Inc. | -15.7 Million CAD | -138.112% |
| Oncolytics Biotech Inc. | -33.71 Million CAD | -10.933% |
| Sernova Corp. | -40.19 Million CAD | 6.961% |